CCL20‐CCR6 Cytokine Network Facilitate Treg Activity in Advanced Grades and Metastatic Variants of Hepatocellular Carcinoma

Tumour immunity regulates tumour restriction to the site of occurrence. Failure of this balance facilitates tumour spread beyond the primary organ of origin. Tregs are known to be recruited in infections, including viral infections like hepatitis B and hepatitis C. Thus, they form a continuum of initial viral infection, an environment of immune suppression by recruitment of Tregs, intrinsic viral‐mediated nuclear transformation and carcinogenesis, and thereafter worsening of progress, including metastasis due to the Tregs suppressing the cell‐mediated destruction of tumour cells. In this study, we obtained advanced grades of hepatocellular carcinoma (HCC) and examined the cytokines that is potentially known to recruit Tregs. We examined the expression of CCL20, the cytokine that recruits Tregs. We isolated Tregs from HCC samples and examined expression of CCR6, the receptor for CCL20 and compared expression in control tissues obtained mainly from subjects with cirrhosis, but no evidence of cancer. The findings of this study indicate that mRNA expression of CCL20 is significantly enhanced, along with expression of mRNA for the cytokines IL17 and IL6. Furthermore, tissue expression of Gamma‐interferon was reduced in HCC. When Tregs were isolated from the liver cancer samples, the expression of CCR6, the only and specific receptor for CCL20, was upregulated in the cancer tissue derived Tregs. Furthermore, STAT3 levels were significantly increased in these tumour‐derived Tregs. This study demonstrates that immune evasion mechanisms are operant in hepatocellular carcinoma through a transcriptional network of CCL20‐IL17‐IL6 cytokines that facilitate immune suppression‐mediated cancer cell elimination and metastasis.

[1]  C. Sautès-Fridman,et al.  The immune response in cancer: from immunology to pathology to immunotherapy , 2015, Virchows Archiv.

[2]  Ye Zheng,et al.  Regulatory T cell identity: formation and maintenance. , 2015, Trends in immunology.

[3]  B. Zhu,et al.  T-cell exhaustion in the tumor microenvironment , 2015, Cell Death and Disease.

[4]  Wei-min Li,et al.  Treg‐specific demethylated region activity in isolated regulatory t lymphocytes is a surrogate for disease severity in hepatocellular carcinoma , 2015, IUBMB life.

[5]  C. Feng,et al.  IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study , 2015, BMC Gastroenterology.

[6]  Jie Ma,et al.  STAT3 cooperates with Twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells. , 2015, Oncology reports.

[7]  Adrian Y. S. Lee,et al.  The relationship between CCR6 and its binding partners: does the CCR6-CCL20 axis have to be extended? , 2015, Cytokine.

[8]  Lixin Wei,et al.  TGF-β Regulates Hepatocellular Carcinoma Progression by Inducing Treg Cell Polarization , 2015, Cellular Physiology and Biochemistry.

[9]  A. Di Giannatale,et al.  The New Deal: A Potential Role for Secreted Vesicles in Innate Immunity and Tumor Progression , 2015, Front. Immunol..

[10]  T. Welling,et al.  Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. , 2014, Gastroenterology.

[11]  S. Aktaş,et al.  Regulatory T cells and their prognostic value in hepatopancreatobiliary tumours. , 2014, Hepato-Gastroenterology.

[12]  Xiao-Fan Wang,et al.  The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma. , 2014, National science review.

[13]  J. Wolchok,et al.  The importance of animal models in tumor immunity and immunotherapy. , 2014, Current opinion in genetics & development.

[14]  D. Kurtz,et al.  Tracking cellular and immune therapies in cancer. , 2014, Advances in cancer research.

[15]  Z. Liang,et al.  Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer , 2013, Oncogene.

[16]  A. B. Lyons,et al.  CC Chemokine Ligand 20 and Its Cognate Receptor CCR6 in Mucosal T Cell Immunology and Inflammatory Bowel Disease: Odd Couple or Axis of Evil? , 2013, Front. Immunol..

[17]  R. Lamaita,et al.  Immune Response Evaluation Through Determination of Type 1, Type 2, and Type 17 Patterns in Patients With Epithelial Ovarian Cancer , 2013, Reproductive Sciences.

[18]  D. Busch,et al.  Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice , 2012, Hepatology.

[19]  Haiyang Xie,et al.  Selective Recruitment of Regulatory T Cell through CCR6-CCL20 in Hepatocellular Carcinoma Fosters Tumor Progression and Predicts Poor Prognosis , 2011, PloS one.

[20]  Ke Wu,et al.  IL-17+ Regulatory T Cells in the Microenvironments of Chronic Inflammation and Cancer , 2011, The Journal of Immunology.

[21]  Hong Wang,et al.  Tumor-Associated Macrophages Recruit CCR6+ Regulatory T Cells and Promote the Development of Colorectal Cancer via Enhancing CCL20 Production in Mice , 2011, PloS one.

[22]  Ti Zhang,et al.  Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma , 2010, Journal of Cancer Research and Clinical Oncology.

[23]  Lin Bin FOXP3~+ regulatory T cells , 2010 .

[24]  Chuan-hai Zhang,et al.  STAT 3 cooperates with Twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells , 2022 .